65,437 trials
HER2 Amplified · Advanced Breast Cancer · Human Epidermal Growth Factor Receptor 2 (HER2)
Primary: Clinical Benefit Rate (CBR) — 23.6 percentage of participants
Asthma
Primary: Safety- Number of Participants With Adverse Events — 16 Participants
Melanoma
Primary: Progression Free Survival at One Year. — 58 percentage of participants PFS at 1 year
Iron Deficiency · Anemia · Kidney Disease
Primary: Mean Change In Hemoglobin From Baseline (Day 1) To Week 5 — 0.84; 0.74; 0.89; 0.80 g/dL — p=0.515
Lymphoma, Hodgkin Disease · Lymphoma · Hodgkin Disease
Primary: Progression-free Survival (PFS) — 89.7; 50 percentage of participants
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Total Score — 15.5; 16.33 units on a scale
Liver Neoplasms · Colonic Neoplasms · Metastatic Cancer to Liver
Primary: Tolerability of Stereotactic Body Radiotherapy (SBRT) Based on Number of Cumulative Acute Toxicities Occurring Within 90 Days of Treatment and Related to SBRT. — 5; 1…
Burn Scars
Primary: Scar Pigmentation, Baseline vs 15-months — 50.93; 49.59 units on a scale
Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation
Primary: Percentage of Subjects Achieved Freedom From Atrial Tachyarrhythmias — 60.6; 60.8; 60 Percentage of participants
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Mental and Behavioral Disorders Due to Harmful Drug Use
Primary: Total Number of Days of Primary Drug Used in the Prior 30 Days — 5.07; 3.61; 4.73 Days
Good Prognosis Metastatic Gestational Trophoblastic Tumor · Hydatidiform Mole · Non-Metastatic Gestational Trophoblastic Tumor
Primary: Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay — 57; 76; 48; 29 Participants
Oral Disease · Smoking
Primary: 7 Day Point Prevalent Abstinence (PPA) — 109; 121 Participants — p=0.13
Fallopian Tubes Cancer · Ovarian Cancer · Peritoneal Cancer
Primary: Number of Participants With Adverse Events — 21 Participants
Lymphoma, Follicular
Primary: Number of Participants With Complete Response at 3 Years — 30 Participants